52% overturnedAppeal outcomes · Laboratory

Denied genetic or genomic testing: what independent reviewers actually decided

Genomic testing is contested almost evenly, and the deciding factor is whether a recognised body already says this patient should be tested.

Molecular pathology, gene panels and proprietary genomic assays ordered to establish a diagnosis, guide therapy or assess inherited risk, and reviewed against policies that enumerate covered indications tightly.

What the independent reviewers decided

52%

overturned by the independent reviewer

301

of 582 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny genetic and genomic testing

  • The policy covers the assay only for enumerated indications and the submitted one is not among them.
  • The result would not change management, in the plan's reading of the request.
  • The panel is broader than the policy allows for the clinical question.
  • The assay is classed as investigational because the policy's evidence review predates the current literature.

What actually carried the cases that won

Guideline support led in 56% of the reversals, with specialty-society criteria almost level with clinical guidelines as the authority — a pairing that appears nowhere else in this corpus at that strength. Genomic testing is an area where professional bodies publish testing criteria explicitly, and the overturned records placed the patient inside a published criterion rather than arguing the test's general validity. Where risk assessment is the question, the family history has to be expressed the way the criteria express it.

What the record showedShare of overturned decisions
A published guideline supported the request56%
Objective findings were documented36%
The diagnosis was confirmed21%
The severity or urgency was documented12%
The functional impact on the patient was documented10%
The condition was documented as chronic or long-standing7%
Conservative treatment was documented as failed7%
Prior treatment was documented3%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

  • Clinical guidelines — in 45% of the overturned decisions
  • Specialty-society criteria — in 44% of the overturned decisions
  • Peer-reviewed literature — in 35% of the overturned decisions
  • Standard of care — in 18% of the overturned decisions
  • FDA labeling — in 4% of the overturned decisions

genetic and genomic testing denials — frequently asked

Is a denied genetic test worth appealing?
Of 582 California independent medical reviews, 301 were overturned — 52%. That is far better than routine laboratory testing fared in the same corpus, and it reflects how much of this policy space rests on published testing criteria a practice can cite.
What is the strongest argument?
A published criterion the patient meets. Guideline support appeared in 56% of the reversals and specialty-society criteria in 44%. Naming the body, the criterion and the fact that puts this patient inside it is the argument these decisions turned on.
How is 'would not change management' answered?
By saying what it changes. The reversals stated the decision the result informs — a therapy choice, a surveillance interval, a surgical decision — rather than asserting clinical utility in the abstract.

Related guides

CO-50 — not medically necessaryOncology denialsMedical necessity appeal letters

Source

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →